3 Steel and Power Company, Specialty Pharmaceuticals Company and Wheels and Suspension Maker Stocks With a Strong Future Roadmap: Sarda Energy, Natco Pharma and Wheels India

Steel power, cancer drug and wheel stocks let investors follow companies that serve a growing part of the Indian economy. Sarda Energy, Natco Pharma and Wheels India cover a steel and power company, a specialty pharmaceuticals company and a wheels and suspension maker.

This list covers three steel power, cancer drug and wheel stocks with complete current figures: Sarda Energy, Natco Pharma and Wheels India. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Steel Power, Cancer Drug and Wheel Stocks?

Steel power, cancer drug and wheel stocks are listed companies that make steel, ferro alloys and power from mines and plants, develop and sell specialty medicines including cancer drugs, and make wheels, suspension and castings for vehicles and railways. Their earnings depend on steel prices, prescription demand and vehicle and rail output.

Steel Power, Cancer Drug and Wheel Stocks at a Glance

On valuation, Sarda Energy and Natco Pharma trade at a P/E below the industry P/E, while Wheels India trades above it, which reflects the growth the market already expects. Readers comparing steel power, cancer drug and wheel stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Steel Power, Cancer Drug and Wheel Stocks Have a Strong Roadmap in India?

Steel power, cancer drug and wheel stocks have a strong roadmap in India because steady growth in steel and power capacity, rising demand for specialty medicines and strong vehicle and rail production keep widening the market for these companies.

• Steel and power. Integrated plants support steady output.
• Specialty pharma. Patients need advanced therapies.
• Wheels and suspension. Vehicles and trains need strong parts.

Why Sarda Energy Features Among These Steel Power, Cancer Drug and Wheel Stocks

Among the steel power, cancer drug and wheel stocks on this list, Sarda Energy and Minerals is a Raipur-based integrated company producing ferro alloys, sponge iron, steel billets and power, supported by its own mines.

Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%.

In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4.

Roadmap: The company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.

What to watch: Track capacity additions, captive mine output and power plant performance.

Why Natco Pharma Features Among These Steel Power, Cancer Drug and Wheel Stocks

Among the ferro alloy, oncology medicine and rim shares on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Why Wheels India Features Among These Steel Power, Cancer Drug and Wheel Stocks

Among the three companies on this list, Wheels India, based in Chennai, manufactures steel wheels for commercial vehicles, tractors and off-highway machines, and is part of the Amalgamations group.

The company has a return on equity of 14.9%, a debt to equity ratio of 0.74 and a market capitalisation of Rs 6,549 crore. The stock trades at a P/E of 39.4, above the industry P/E of 36.9.

Revenue rose from Rs 3,979 crore in FY22 to Rs 5,488 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 74.2 crore in FY22 to Rs 158 crore in FY26, which works out to a compound annual growth rate of 20.8%. In the June 2026 quarter, revenue grew 17.7% year on year to Rs 1,493 crore, while net profit rose 27.3% to Rs 38.9 crore.

Roadmap: Demand from trucks, tractors and construction equipment, along with exports and a growing aftermarket, supports its volumes. The company is also working on lighter wheels and new products for farm and construction machines.

What to watch: Follow farm and construction equipment demand and steel prices.

Sarda Energy vs Natco Pharma vs Wheels India on Key Financials

The table below sets the three steel power, cancer drug and wheel stocks side by side on revenue, profit and margin, using reported figures.

Natco Pharma posts the highest return on equity in this group at 15.4%. Sarda Energy has the largest FY26 revenue at Rs 5,928 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with steel power, cancer drug and wheel stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Steel Power, Cancer Drug and Wheel Stocks

Every theme carries risks that deserve a check before any decision. For these steel power, cancer drug and wheel stocks, the main points are: Long-term ferro alloy, oncology medicine and rim shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Commodity prices. Selling prices follow global and domestic markets.
• Pricing pressure. Generic prices can change by market.
• Production cycles. Vehicle output can vary with demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter steel power, cancer drug and wheel stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Steel Power, Cancer Drug and Wheel Stocks

Steel power, cancer drug and wheel stocks reward investors who follow demand trends, order books and margins together. Sarda Energy, Natco Pharma and Wheels India each have a clear plan to grow. Based on the 12 November 2026 close, Sarda Energy trades at Rs 447.6, Natco Pharma at Rs 808.8 and Wheels India at Rs 2,447.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these steel power, cancer drug and wheel stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track steel power, cancer drug and wheel stocks, set price alerts and get research-backed stock ideas.

What are steel power, cancer drug and wheel stocks?

Ans. Steel power, cancer drug and wheel stocks are listed companies that make steel, ferro alloys and power from mines and plants, develop and sell specialty medicines including cancer drugs, and make wheels, suspension and castings for vehicles and railways. Their earnings depend on steel prices, prescription demand and vehicle and rail output. This list looks at three of them, Sarda Energy, Natco Pharma and Wheels India, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.

Which steel power, cancer drug and wheel stocks are covered in this list?

Ans. This list covers Sarda Energy, Natco Pharma and Wheels India. Based on the 12 November 2026 close, Sarda Energy traded at Rs 447.6, Natco Pharma at Rs 808.8 and Wheels India at Rs 2,447.8. Their return on equity ranges from 14.9% to 15.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 21.0%.

Why do steel power, cancer drug and wheel stocks have a strong future roadmap in India?

Ans. Steel power, cancer drug and wheel stocks have a strong roadmap in India because steady growth in steel and power capacity, rising demand for specialty medicines and strong vehicle and rail production keep widening the market for these companies. The main drivers are as follows. Steel and power. Integrated plants support steady output. Specialty pharma. Patients need advanced therapies. Wheels and suspension. Vehicles and trains need strong parts. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sarda Energy performed financially?

Ans. Revenue rose from Rs 3,964 crore in FY22 to Rs 5,928 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 808 crore in FY22 to Rs 1,063 crore in FY26, which works out to a compound annual growth rate of 7.1%. In the June 2026 quarter, revenue grew 0.2% year on year to Rs 1,717 crore, while net profit rose 9.4% to Rs 463 crore. The company has a return on equity of 15.0%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 16,079 crore. The stock trades at a P/E of 14.0, below the industry P/E of 22.4. Looking ahead, the company is growing capacity in steel and power while using captive mines to support its cost base. An integrated model lets it capture margin at several steps of production.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

How has Wheels India performed financially?

Ans. Revenue rose from Rs 3,979 crore in FY22 to Rs 5,488 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 74.2 crore in FY22 to Rs 158 crore in FY26, which works out to a compound annual growth rate of 20.8%. In the June 2026 quarter, revenue grew 17.7% year on year to Rs 1,493 crore, while net profit rose 27.3% to Rs 38.9 crore. The company has a return on equity of 14.9%, a debt to equity ratio of 0.74 and a market capitalisation of Rs 6,549 crore. The stock trades at a P/E of 39.4, above the industry P/E of 36.9. Looking ahead, demand from trucks, tractors and construction equipment, along with exports and a growing aftermarket, supports its volumes. The company is also working on lighter wheels and new products for farm and construction machines.

What risks should investors check before buying steel power, cancer drug and wheel stocks?

Ans. Investors should check a few risks before buying steel power, cancer drug and wheel stocks. Commodity prices. Selling prices follow global and domestic markets. Pricing pressure. Generic prices can change by market. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of steel power, cancer drug and wheel stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.